Bobak Azamian

Bobak Azamian

Director Ejecutivo en TARSUS PHARMACEUTICALS, INC. .

Fortuna: 52 M $ al 31/05/2026

48 años
Health Technology
Consumer Services
Finance

Perfil

Bobak Azamian was the founder of Metavention, Inc., founded in 2012, where the title held was President & Chief Medical Officer in 2018.
Dr. Azamian is the founder of Tarsus Pharmaceuticals, Inc., founded in 2017, holding the titles of Chairman, President & Chief Executive Officer since 2022.
Dr. Azamian is the founder of Vibrato Medical, Inc., founded in 2016, serving as Director.
Dr. Azamian is also the founder of Novel Therapeutics Co...
Dr. Azamian currently serves as Director at Osanni Bio, Inc. since 2022.
Former positions include Director at OCTANe, Principal at Amgen, Inc., Principal at Versant Venture Management LLC, and Senior Associate at Third Rock Ventures LLC.
Education includes a doctorate from the University of Oxford, an undergraduate degree from William Marsh Rice University, and a doctorate from Harvard Medical School.

Participaciones conocidas en empresas públicas

EmpresaFechaNúmero de accionesValoraciónFecha de valoración
17/06/2026 881.412 ( 2,05 % ) 52 M $ 31/05/2026

Cargos activos de Bobak Azamian

EmpresasCargoInicio
TARSUS PHARMACEUTICALS, INC. Director Ejecutivo 01/09/2018
Fundador 01/12/2016

Antiguos cargos conocidos de Bobak Azamian.

EmpresasCargoFin
Director Ejecutivo 01/01/2018
Novel Therapeutics Co.
Fundador -
Director/Miembro de la Junta -
Inversor de Capital Privado -
AMGEN INC. Corporate Officer/Principal -
Ver el detalle de la experiencia de Bobak Azamian.

Formación de Bobak Azamian.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Relaciones

7

Relaciones de 1er grado

11

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Empresas relacionadas

Empresas privadas11

Health Technology

Consumer Services

Consumer Services

Finance

Finance

Consumer Services

Commercial Services

Health Technology

Health Technology

Health Technology

Novel Therapeutics Co.